Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults from 18 to 75 years old~* neuropathic painful condition following a thoracotomy or thoracoscopy for at least 3 months~Exclusion criteria:~* cardiovascular risk~* unstable diabetes mellitus~* allergy for terbutaline~* hypokaliemia without treatment~* untreated hypothyroidism~* HIV- or chemotherapy-induced neuropathy~* cancer being treated by chemo- or radio-therapy~* concomitant treatment with β-blockers, tricyclic ADs or morphine~* concomitant pain more severe than neuropathic pain- pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- first period with terbutaline and second period with placebo (Type: OTHER): The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
- first period with placebo and second period with terbutaline. (Type: OTHER): The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).